Semiannual Report — FY2026 H1

During the current interim consolidated accounting period, revenue declined due to factors including adjustments to the supply volume of GBS-007, despite progress in the manufacturing and delivery of biosimilars, while operating profit and ordinary profit increased significantly as a result of measures to reduce manufacturing costs. In addition, a gain on the sale of investment securities was recognized, increasing interim net income attributable to owners of the parent. In the cell therapy business, the filing also describes progress including the publication of final analysis results from the cerebral palsy clinical research and GMP preparations toward the start of clinical trials.